AU2024900264A0 - Exospmes isolated from Wharton’s jelly have emerged as a novel therapeutic approach for the treatment of Alzheimer's disease. - Google Patents

Exospmes isolated from Wharton’s jelly have emerged as a novel therapeutic approach for the treatment of Alzheimer's disease.

Info

Publication number
AU2024900264A0
AU2024900264A0 AU2024900264A AU2024900264A AU2024900264A0 AU 2024900264 A0 AU2024900264 A0 AU 2024900264A0 AU 2024900264 A AU2024900264 A AU 2024900264A AU 2024900264 A AU2024900264 A AU 2024900264A AU 2024900264 A0 AU2024900264 A0 AU 2024900264A0
Authority
AU
Australia
Prior art keywords
exospmes
wharton
jelly
emerged
alzheimer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024900264A
Inventor
Mahdi Jafarlou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jafarlou Mahdi Dr
Original Assignee
Jafarlou Mahdi Dr
Filing date
Publication date
Application filed by Jafarlou Mahdi Dr filed Critical Jafarlou Mahdi Dr
Publication of AU2024900264A0 publication Critical patent/AU2024900264A0/en
Pending legal-status Critical Current

Links

AU2024900264A 2024-02-06 Exospmes isolated from Wharton’s jelly have emerged as a novel therapeutic approach for the treatment of Alzheimer's disease. Pending AU2024900264A0 (en)

Publications (1)

Publication Number Publication Date
AU2024900264A0 true AU2024900264A0 (en) 2024-02-15

Family

ID=

Similar Documents

Publication Publication Date Title
HUP0201213A2 (en) Pirimidinyl, pirazinyl and thiadiazolyl phenylalanin derivatives which treat vla-4 related disorders and pharaceutical compositions containing them
WO2005097763A3 (en) 1,3,4-oxadiazol-2-ones as ppar delta
WO2002016333A3 (en) Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease
EA200601494A1 (en) IMIDAZOLIC CONNECTIONS FOR THE TREATMENT OF NEURODEGERATIVE DISORDERS
WO1999065449A3 (en) INHIBITORS OF TRANSCRIPTION FACTOR NF-λB
SI2527315T1 (en) Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2003027068A3 (en) Substituted amines for the treatment of neurological disorders
WO2020263967A8 (en) 2h-indazole derivatives and their use in the treatment of disease
WO2021021979A3 (en) Hdac6 inhibitors and uses thereof
IL179160A0 (en) Substituted n-aryl benzamides and related compounds for treatment of amyloid diseases and synucleinopathies
WO2002072585A3 (en) Substituted pyrazolopyrimidines and thiazolopyrimidines used as analgesics
WO2000059489A3 (en) Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites
WO2000043354A3 (en) Multicyclic compounds which inhibit leukocyte adhesion mediated by vla-4
WO2005014041A3 (en) Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
WO2004055201A3 (en) Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
DE60015508T2 (en) C-16 UNAUDITED FP-SELECTIVE PROSTAGLANDIN ANALOGUE
AU2024900264A0 (en) Exospmes isolated from Wharton’s jelly have emerged as a novel therapeutic approach for the treatment of Alzheimer's disease.
EP1958939A3 (en) Pyrazole-amine compounds for the treatment of neurodegenerative disorders
KR100254930B1 (en) Cyclopropenone derivatives
WO2001019819A3 (en) Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
WO2021242844A8 (en) Grk2 inhibitors and uses thereof
WO2010005581A4 (en) Niacin compositions for reduction of amyloid beta peptide 42 (abeta 42) production and for treatment of alzheimer's disease (ad)
WO2000043413A3 (en) Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by vla-4